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Background: Substantial experimental evidence supports that reactive species mediate secondary damage after
traumatic spinal cord injury (SCI) by inducing oxidative stress. Removal of reactive species may reduce secondary
damage following SCI. This study explored the effectiveness of a catalytic antioxidant - Mn (III) tetrakis (4-benzoic
acid) porphyrin (MnTBAP) - in removing reactive oxygen species (ROS), reducing oxidative stress, and improving
functional recovery in vivo in a rat impact SCI model. The efficiency of MnTBAP was also compared with that of
methylprednisolone – the only drug used clinically in treating acute SCI.
Results: In vivo measurements of time courses of ROS production by microdialysis and microcannula sampling in
MnTBAP, methylprednisolone, and saline (as vehicle control)-treated SCI rats showed that both agents significantly
reduced the production of hydrogen peroxide, but only MnTBAP significantly reduced superoxide elevation after
SCI. In vitro experiments further demonstrated that MnTBAP scavenged both of the preceding ROS, whereas
methylprednisolone had no effect on either. By counting the immuno-positive neurons in the spinal cord sections
immunohistochemically stained with anti-nitrotyrosine and anti-4-hydroxy-nonenal antibodies as the markers of
protein nitration and membrane lipid peroxidation, we demonstrated that MnTBAP significantly reduced the
numbers of 4-hydroxy-nonenal-positive and nitrotyrosine-positive neurons in the sections at 1.55 to 2.55 mm and
1.1 to 3.1 mm, respectively, rostral to the injury epicenter compared to the vehicle-treated animals. By behavioral
tests (open field and inclined plane tests), we demonstrated that at 4 hours post-SCI treatment with MnTBAP and
the standard methylprednisolone regimen both significantly increased test scores compared to those produced by
vehicle treatment. However, the outcomes for MnTBAP-treated rats were significantly better than those for
methylprednisolone-treated animals.
Conclusions: This study demonstrated for the first time in vivo and in vitro that MnTBAP significantly reduced the
levels of SCI-elevated ROS and that MnTBAP is superior to methylprednisolone in removing ROS. Removal of ROS
by MnTBAP significantly reduced protein nitration and membrane lipid peroxidation in neurons. MnTBAP more
effectively reduced neurological deficits than did methylprednisolone after SCI - the first most important criterion
for assessing SCI treatments. These results support the therapeutic potential of MnTBAP in treating SCI.
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Traumatic spinal cord injury (SCI) is worsened by
secondary damage processes caused by the overpro-
duction of endogenous deleterious substances [1,2].
Reactive species (RS), including reactive oxygen species
(ROS) and reactive nitrogen species (RNS), are believed to
contribute to secondary damage after SCI by oxidatively
damaging proteins, DNA, and phospholipids [3-5]. ROS
include superoxide anion (O2
•-), hydrogen peroxide (H2O2)
and hydroxyl radical (•OH). O2
•- is produced through
several aerobic pathways during normal metabolism, and
superoxide dismutase (SOD) converts O2
•- into H2O2.
H2O2 is reduced to H2O by catalase, glutathione peroxid-
ase (GPx), and thioredoxin. A dynamic equilibrium exists
between the potential for oxidative damage and the anti-
oxidant defense capacity. Disruption of this balance
produces excessive O2
•- and H2O2, which can produce
•OH by the metal-catalyzed Haber-Weiss/Fenton reaction
[6,7]. ROS attack polyunsaturated fatty acids in cell mem-
branes, triggering free radical chain reactions to cause
membrane lipid peroxidation (MLP) to produce aldehydes
such as malondialdehyde (MDA) and 4-hydroxy-nonenal
(HNE) - the by-products of MLP. HNE damages proteins
by forming covalent aldehyde-protein complexes [8]. This
compromises protein function by altering secondary and
tertiary structure, further impairing cells [9,10]. Excessive
O2
•- can also react with RNS nitric oxide to form powerful
oxidant peroxynitrite (ONOO-). Peroxynitrite in turn
reacts with SOD to form a nitronium-like intermediate,
which nitrate tyrosine in proteins to produce nitrotyrosine
(Ntyr), a marker of protein nitration [11,12]. Hence, HNE-
positive or Ntyr-positive neurons might be functionally
impaired and more susceptible to subsequent death.
Substantial experimental evidence supports RS as import-
ant mediators of secondary damage after SCI [13-15]. We
and others have demonstrated that the levels of O2
•- [16],
H2O2 [17],
•OH [18], catalytic iron [19], nitric oxide [20,21],
ONOO- [20,22], and the products of oxidation and nitra-
tion of proteins [20,23-26] and MLP [26-29] all significantly
increased following SCI. The increased levels of RS are
sufficient to cause oxidative damage to major cellular com-
ponents [30,31], neuronal death by necrosis and apoptosis
[32-34], and neurological dysfunction [32] in uninjured rat
spinal cords. These results suggest that RS-caused oxidative
stress is a major pathway of secondary damage after
SCI. Therefore, removing RS with a broad-spectrum
RS scavenger may reduce secondary SCI.
Metalloporphyrins, as a novel class of catalytic antioxi-
dants, not only scavenge a wide range of RS such as O2
•- ,
H2O2, ONOO
-, and lipid peroxyl radicals [35], but also
modulate RS-based redox signaling pathways [36]. It was
reported that the in vivo actions of Mn (III) complexes
probably do not depend upon catalysis of the dismutation
reaction, but the complex can be reduced by bothenzymatic and spontaneous routes, and the resultant Mn
(II) complex can be reoxidized by O2
•- with a rate constant
of ~ 4 × 109 M-1 S-1 [37]. The metalloporphyrin Mn (III)
tetrakis (4-benzoic acid) porphyrin (MnTBAP) possesses
SOD and catalase-like activity [38], and also scavenges
ONOO- [39]. It is also a potent inhibitor of MLP [40].
MnTBAP not only converts O2
•- to H2O2, but it also cata-
lyzes dissociation of H2O2 to water - the catalase activity;
this blocks the Haber-Weiss pathway for •OH production,
thereby blocking ROS damage. In the central nervous
system, cerebroventricular injection of MnTBAP inhibited
kainate-induced mitochondrial O2
•- production, DNA
oxidation and neuronal loss in the hippocampus [41].
We demonstrated in vivo that MnTBAP reduced
ONOO--induced oxidation and nitration of proteins
[30] and MLP [31] in the rat spinal cord. It prevented
ONOO-- and •OH-induced necrotic and apoptotic cell
death [33,34]. These results suggest that the catalytic anti-
oxidant MnTBAP may be beneficial as antioxidant therapy
after SCI owing to its cell permeability, low toxicity, and
broad scavenging of RS, and therefore warrant closer
examination. However, the ROS-reduction ability of
MnTBAP has never been tested in vivo in an experimental
SCI model.
A high-dose regimen of methylprednisolone (MP)
improves neurological recovery from SCI in humans
[42,43]. MP is the only drug currently used clinically in
treating acute SCI and its high-dose regimen has become
the standard of treatment. To evaluate the treatment
potential of a new candidate, it is critical to compare its
efficacy with that of existing treatment agents. The goals of
the present study were 1) To evaluate the ability of
recently established intrathecal optimal dose of MnTBAP
[44] to reduce O2
•- and H2O2 produced in the extracellular
space of the rat spinal cord following SCI and to compare
the ROS-reducing abilities between the optimal dose of
MnTBAP and the standard regimen of MP in in vivo and
in vitro experiments. 2) To examine the capability of the
optimal dose of MnTBAP to protect against RS-induced
neuronal oxidative damage following SCI as an addition to
our previous funding that a dose lower than the optimal
dose of MnTBAP significantly reduced oxidative stress and
neuron loss, but MP had no effect on either [45]. 3) To
compare the efficiency between MnTBAP and MP in
improving functional recovery by behavioral tests. The
resulting data would explore the potential of MnTBAP for
antioxidant therapy following SCI.
Methods
Male Sprague–Dawley rats (200–250 g) were used in all
in vivo experiments. The procedures in the rats were ap-
proved by the University of Texas Medical Branch Animal
Care and Use Committee and are in accord with the
National Institutes of Health’s guide for the Care and Use
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animal suffering and the number of animals used.Examination of the ability of MnTBAP and MP to remove
ROS after SCI
To evaluate the ability of MnTBAP and MP to reduce
H2O2 and O2
• ─ produced after SCI, the time courses of O2
•-
and H2O2 productions in the extracellular space of the rat
spinal cord were measured by microdialysis and micro-
cannula sampling respectively, according to our published
methods [16,17] in three groups of rats treated with
MnTBAP, MP, and saline (vehicle control) upon injury
(n = 6 for each group). The procedures for anesthesia,
animal surgery, preparation and insertion of microdialysis
fiber and microcannula, microdialysis and microcannula
sampling, and impact injury are described in detail in our
previous publications [16,17,20].Animal preparation
The rats were anesthetized with sodium pentobarbital
(35 mg/kg body weight) intraperitoneally (ip), followed
by urethane (500 mg/kg) to maintain anesthesia until
sacrifice. After the rats were fully anesthetized, a lamin-
ectomy was performed on vertebrae T12–L1. A pin was
inserted into one end of a microdialysis fiber or a
microcannula and glued in place by using SuperGlue
(Kwik·Fix, Chemence,Inc.; Alpharetta, GA, USA). The
pin was pushed laterally through the gray matter of the
cord at T13, and the fiber or cannula was pulled through
the cord following the pin until the trailing marker just
disappeared into the cord. This placed the dialysis zone
or the holes in the gray matter of the cord. The dorsal
half of the L5 vertebra was also removed, and a small
hole was made in the exposed dura. A perfusing catheter
(200 μm inside diameter and 300 μm outside diameter,
11 kDa molecular weight cutoff; Filtral AN 69-HF,
Hospal Industrie, Meyzieu, France) was inserted through
the hole 1 cm caudal to the terminal cistern in the rat
intrathecal space as described previously [46]. There was
enough space to implant the catheter without injuring
the nerves and there was no cord in this area that might
be damaged by the catheter. The animal was then
clamped in a frame by attachment to its dorsal vertebral
processes. Body temperature was maintained at 37–38°C
throughout the experiment by utilizing feedback from
a rectal probe to a heating blanket (Harvard homeo-
thermic blanket control unit; Les Ulis, France). The
pin was then cut off and the microdialysis fiber or
microcannula was attached to a microdialysis pump
(CMA, Microdialysis AB, Solna, Sweden) with a length of
polyethylene (PE)-50 tubing for sampling. The catheter
was also attached to another syringe pump through a
PE-20 tube for drug delivery.The microdialysis fibers or microcannulae were made as
follows: Two 1 mm wide ink marks flanking a 2-mm area
were made on a microdialysis fiber (Spectra/Por RC; 200
μm inside diameter, Spectrum Laboratories, Inc, Houston,
TX, USA). Then, the fibers were coated with a thin layer of
silicone rubber (3140 MIL-A-46146 RTV, Dow Corning
Corporation, Midland, MI, USA) with a final external diam-
eter of 220 μm. For sampling H2O2, the 2-mm dialysis zone
was uncoated [17]. For measuring O2
•- production, two pairs
of holes were made within the 2-mm zone through the wall
of a completely coated fiber, allowing administered
cytochrome c to diffuse through the holes owing to the
concentration gradient, as we previously described [16].
Microdialysis and microcannula sampling and impact injury
A pool was formed around the exposed spinal cord.
Mineral oil (37°C) was poured into the pool, and the
temperature of the oil was maintained at 36–37°C by
utilizing feedback from a thermosensor placed in the oil
pool to a heating lamp set above the pool (Physitemp
Instruments G15, Inc., Clifton, NJ, USA). Artificial
cerebrospinal fluid (ACSF), composition in mM: Na+ 151.1,
K+ 2.6, Mg2+ 0.9, Ca2+ I.3, C1- 122.7, HCO3
- 21.0, HPO4
2-
2.5 and glucose 3.87.) was pumped through the fiber at a
rate of 5.0 μl/min or the cannula at a rate of 15.0 μl/min.
ACSF was bubbled with 95% O2/5% CO2 prior to each
experiment to adjust the pH to between 7.0 and 7.4. Sample
collection was begun 75 min after insertion of the fiber or
cannula into the cord, allowing the release of substances
owing to the insertion of the fiber or cannula to subside to
a stable baseline. Fluid was collected from the outlet end of
the fiber or cannula in plastic vials in ice. After 60 min of
fluid collection at 20 min per sample to obtain a basal level,
the mineral oil was removed and the spinal cord was
injured over the zone containing the fiber or cannula by
dropping a 10-g rod through a guide tube 2.5 cm down to
the cord (25 g·cm injury force), originally developed by
Allen [47]. After impact injury of the cord, the pool was
refilled with mineral oil and samples were collected over 20
min intervals for 5 h.
The New York University (NYU) spinal cord impactor,
designed based on the weight drop method, is a standard
device for an impact injury [48]. However, in the above
experimental procedures, the microdialysis fiber or
microcannula, and the drug delivery catheter have to be
implanted into the rat and connected to pumps, and the rat
has to be connected to a heating blanket and a heating
lamp, an oil pool has to be made around the exposed cord,
and basal samples have to be collected prior to injury.
Therefore it was impossible to use the NYU device to
perform an injury for these types of experiments. The valid-
ation of our weight drop method was demonstrated in our
previous publications using microdialysis or microcannula
sampling [16,17,20].
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It was reported that MnTBAP poorly penetrates the
blood–brain barrier [49]. Therefore, we established an
optimal intrathecal dose of 4 mg/kg MnTBAP for its
ability to protect against MLP and neuron death [44]. In
the present study, the established optimal dose was admi-
nistered through the implanted catheter into the intrathecal
space of the rat spinal cord in the MnTBAP-treated group.
MnTBAP was dissolved in 0.1 M NaOH, the solution was
diluted with 0.9% saline, and the pH was adjusted to
7.1-7.3 [49]. Due to the low solubility of MnTBAP, 10
mg/mL MnTBAP was administered approximately
one hour before injury so that the optimal dose of
MnTBAP could be completely administered at the time
point of impact injury at a rate of 1.5 μl/min.
Methylprednisolone sodium succinate (MPSS), a water-
soluble derivative of MP, is the form used in animal experi-
ments and in clinical treatments of SCI. MPSS quickly
breaks down to MP, the effective component of MPSS,
following its administration. The standard regimen of
MPSS, given intravenously (iv), consists of 30 mg/kg as a
bolus dose followed by 5.4 mg/kg/h as a maintenance dose.
The maximum MP concentration ratio of cerebrospinal
fluid to blood is nearly 20% following iv administration
[50]. According to this ratio, a 6 mg/kg bolus dose and a
1.08 mg/kg/h maintenance dose of MPSS given intra-
thecally equals the standard clinical regimen of MPSS given
iv. Therefore, in the MPSS-treated group, a 6 mg/kg bolus
dose was administered into the intrathecal space of the rat
spinal cord over a 10-min period and was completed at the
time point of impact injury. Then the 1.08 mg/kg/h main-
tenance dose was administered continually for three hours
starting at 2 hour post-SCI. A total of 9.24 mg/kg MPSS
was administered into the intrathecal space of every rat at a
rate of 1.5 μl/min.
Examination of the ability of MnTBAP and MP to remove
ROS in vitro
To compare the abilities of MnTBAP and MP to scavenge
H2O2 in vitro, three groups of experiments were conducted:
2.5 μM H2O2 treated with ACSF, with 20 mg/L MnTBAP,
and with 30 mg/L MPSS, as shown in Table 1. All reagentsTable 1 In vitro removal of H2O2 by MnTBAP and MPSS
Sample Reagent added
H2O2 MnTBAP MPSS
(5.0 μM) (40 mg/L) (60 m
Control 200 μl 0 0
MnTBAP-treated 200 μl 200 μl 0
MPSS-treated 200 μl 0 200 μwere dissolved in ACSF. The final volume of solution was
400 μl. In each group, three samples of identical compos-
ition were prepared. After incubation of the mixture of
H2O2 and drugs at 37°C for 30 min, 100 μl of each sample
was mixed with 100 μl of water containing 1 mM salicylate
and 0.2 mM FeCl2 and allowed to react for 5 min. The Fe
2+
catalyzed dissociation of the remaining H2O2 to pro-
duce •OH by the Fenton reaction: Fe2+ + H2O2 →
Fe3+ + •OH + OH−. The produced •OH attacks salicylate
to produce 2,3- and 2,5- dihydroxybenzoic acid (2,3- and
2,5-DHBA), which were measured by high-pressure
liquid chromatography (HPLC), as described below.
Comparison of 2,3-DHBA concentrations between con-
trol and MnTBAP- or MPSS-treated samples established
the ability of these drugs to scavenge H2O2 in vitro.
The abilities of MnTBAP and MPSS to scavenge O2
•-
were also compared in vitro. As for measuring H2O2,
three groups of experiments were similarly performed as
shown in Table 2. All reagents were dissolved in ACSF
and the final volume of solution for each sample was
400 μl. In each group, three samples of identical
composition were prepared. O2
•- was generated by the
xanthine and xanthine oxidase pair as reported [51] and
as we previously demonstrated in vivo [18]. O2
•- gene-
ration was started by adding xanthine to a solution
containing xanthine oxidase and cytochrome c in ACSF
in the vial. Xanthine oxidase catalyzed xanthine to
produce O2
•-, and the O2
•- generated in turn reduced
cytochrome c to reduced cytochrome c. The absorbance
of reduced cytochrome c was measured spectrophoto-
metrically at 2 min following addition of xanthine, as
described below. Comparison of the absorbance of
reduced cytochrome c between control and MnTBAP- or
MPSS-treated samples provided the ability of these drugs
to scavenge O2
•─ in vitro.
Analysis of H2O2 and O2
•- in microdialysates, perfusates,
and in vitro reactants
H2O2 in the collected microdialysates were measured by
converting the sampled H2O2 to
●OH in the collecting
vials by the Fenton reaction using a unique method





200 μl 400 μl 2.5 μM H2O2
0 400 μl 2.5 μM H2O2
20 mg/L MnTBAP
l 0 400 μl 2.5 μM H2O2
30 mg/L MPSS
Table 2 In vitro removal of O2
•- by MnTBAP and MPSS













Control 100 μl 100 μl 100 μl 0 0 100 μl 400 μl 50 μM cytochrome c, 25 unit/L
xanthine oxidase, 20 μM xanthine
MnTBAP-treated 100 μl 100 μl 100 μl 100 μl 0 0 400 μl 50 μM cytochrome c, 25 unit/L xanthine
oxidase, 20 μM xanthine, 20 mg/L MnTBAP
MPSS-treated 100 μl 100 μl 100 μl 0 100 μl 0 400 μl 50 μM cytochrome c, 25 unit/L xanthine
oxidase, 20 μM xanthine, 30 mg/L MPSS
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were pre-added to the collecting vial (1:1, microdialysate :
solution). H2O2 sampled through the microdialysis fiber
immediately reacts with FeCl2, while reaching the solution
in the collecting vials to generate ●OH in the vials by the
Fenton reaction. The ●OH produced in the collecting vials
rapidly attacks salicylate to produce 23- and 2,5-DHBA.
The DHBAs in the collecting vials in the in vivo and in
the reactants in the in vitro experiments were measured
by HPLC with electrochemical detection [52]. A Shimadzu
(Shimadzu Scientific Instruments Inc., Columbia, MD,
USA) HPLC (LC-10AD pump, SIL-10AXL auto injector)
with a Phenomenex C18 (3-mm particle, 15 cm × 4.6 mm,
Phenomenex U.S.A., Torrance, CA, USA) analytical col-
umn and an ESA Coulochem II electrochemical detector
(ESA, Inc., Chelmsford, MA, USA) were used in this
experiment. The voltages of the guard cell and analytical
electrode were 750 mV and 250 mV, respectively. The mo-
bile phase was 0.03 M citric acid, 0.03 M sodium acetate,
and 20% methanol at an elution flow rate of 0.7 ml/min.
2,3-DHBA as a specific marker of ● OH production was
calibrated to the concentration of H2O2 by using a stand-
ard curve of [H2O2] vs [2,3-DHBA], as previously de-
scribed in detail [17].
The levels of O2
•- in the extracellular space of the cord
were measured by perfusing cytochrome c through a
microcannula inserted into the gray matter of the cord
and measuring reduced cytochrome c by using the
method that we developed previously [16]. After the
initial ACSF perfusion, the perfusing fluid was changed
to a cytochrome c solution (50 μM in ACSF) to capture
the O2
•- in the extracellular space of the cord. The
collected perfusates were centrifuged at 12,000 × g for
10 min to precipitate blood and tissue fragments. The
absorbance of reduced cytochrome c in the supernatant
in the in vivo experiments and in the reactants in the
in vitro experiments was measured by a BioSpec-1601
spectrophotometer (Shimadzu Scientific Instruments,
Inc., Columbia, MD, USA) at a characteristic absorbance
wavelength of 550 nm. The perfusing fluid (cytochrome
c solution) in the in vivo experiments or the mixturewithout adding xanthine in the in vitro experiments was
used as the reference in the measurement [16].
Examination of the ability of MnTBAP to protect against
oxidative stress after SCI
In the experiments for examining the effect of MnTBAP
protection against oxidative stress, two groups of rats
treated with MnTBAP or saline as vehicle control (n = 4
for each group) were used.
Animal preparation, drug administration and tissue
processing
The rats were anesthetized with sodium pentobarbital
(50 mg/kg, ip) without maintenance doses. Following a
laminectomy on vertebra T13, the cords were injured by
using the standard NYU spinal cord impactor. A 10 g
rod was dropped 1.25 cm onto the exposed cord (12.5 g.
cm force) using the NYU device. Immediately after SCI,
approximately 20 μl (depending on the weight of the rat)
of MnTBAP (4 mg/kg in saline) or saline as vehicle
control was administered through the implanted catheter
into the intrathecal space and completed within approxi-
mately 10 min. After injury and drug administration, the
incision was surgically repaired. The body temperature of
the rat was maintained by using a heating pad during
surgery and until the rat awakened.
At 24 h post-SCI, the rat was re-anesthetized and
perfused transcardially with saline followed by 4% parafor-
maldehyde in phosphate-buffered saline (PBS, pH 7.2-7.4).
Following the perfusion, 15-mm segments centered at the
injury site were removed and fixed in the same fixative for
another 24 h at 4°C. The fixed cords were dehydrated and
embedded in paraffin. The serial sections (10 μm thickness)
were cut with a microtome and mounted on glass slides
coated with poly-L-lysine (five sections per slide) for
immuno-staining. Every 10th slide in the series was
deparaffinized and stained with 0.1% cresyl violet (ACROS,
New Jersey, USA) in sodium acetate buffer for 30 min
[34]. These sections were observed under a light micro-
scope to locate the section with the lowest neuron density
as the injury epicenter (defined as distance zero).
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To evaluate oxidative damage, HNE and Ntyr, as mar-
kers of MLP and protein nitration respectively, were
used for immunohistochemical staining according to our
published procedures [30,31,45]. The primary antibodies
were HNE polyclonal antiserum (1:100, rabbit-anti-HNE,
from Alpha Diagnostic Intl., San Antonio, TX, USA) and
anti-Ntyr (1:500, mouse-anti-Ntyr, from Cayman Chemical,
Ann Arbor, MI, USA). The secondary antibody was bioti-
nylated goat-rabbit-IgG or biotinylated goat-mouse-IgG
respectively (Invitrogen, Camarillo, CA, USA). Ready-to
-use histostain-plus streptavidin-horse radish peroxidase
(Invitrogen, Camarillo, CA, USA) was used to label
biotinylated antibodies, then sections were stained with a
liquid 3,3’-diaminobenzidine substrate kit (Invitrogen,
Camarillo, CA, USA).
HNE- and Ntyr-positive neurons were also visualized
by immuno-fluorescence-double staining with antibodies
against HNE and neuron-specific enolase (NSE) or Ntyr
and NSE. In brief, the sections were immuno-stained
with a first primary antibody, rabbit-anti-HNE (1:100,
Alpha Diagnostic Intl., San Antonio, TX, USA), or rabbit
anti-Ntyr (1:200, Cayman chemical, Ann Arbor, MI,
USA) and labeled fluorescently with a first secondary
antibody, anti-rabbit Alexa Fluor 488 (green, Invitrogen,
Camarillo, CA, USA). After the sections were incubated
in goat serum for 30 min, the sections were immuno-
stained with a second primary antibody, mouse-anti-NSE
(1:100, Dako Cytomation, Glostrup, Denmark) and then
labeled with a second secondary antibody, anti-mouse
Alexa Flour 594 (red, Invitrogen, Camarillo, CA, USA).
These sections were washed in PBS three times and
cover slipped with Pro-Long Gold anti-fade reagent
(Invitrogen, Camarillo, CA, USA). A fluorescence micro-
scope (Olympus model BX-51) was used for photomicro-
graphs with green (AF-488) and red (AF-594) filters.
Cell counting
MnTBAP protection against oxidative stress was evalu-
ated spatially by counting the immuno-stained neurons
on the sections at different distances rostral to the
epicenter. The images of immunohistochemically stained
sections were observed under a light/fluorescence micro-
scope (Olympus BX51) and captured by a digital camera
(Olympus DP70 microscope digital camera) with a com-
puter system and software for processing photographs.
HNE- and Ntyr-positive neurons were identified based on
the positively immuno-stained cytoplasm with bright
nuclei and the morphology of neurons. The positively
immuno-stained neurons in the gray matter of the cord in
each section were counted in areas of the ventral left and
ventral right quarters. Quarters were defined by horizontal
and vertical lines drawn crossing the central canal in the
center of the sections. This area of gray matter includesmotoneurons, middle- and small-sized neurons, and glial
cells. The neurons in each left or right quarter were
counted three times and the counts averaged for that
quarter; then the counts in the left and right quarters were
averaged for that section. To avoid bias, the person
processing the cord into sections and the person counting
the cells in the sections were blinded. This counting
method has been validated by our previous publications
[20,44,45,53] and by those of many others.
Evaluation of the ability of MnTBAP and MP protection
against neurological dysfunction after SCI
SCI causes hind limb paralysis and inability of the rat to
support its body weight, so the scrotum of male rats
touched and dragged around the bottom of cage - in-
creasing the incidence of infection. Therefore, in most
publications using behavioral tests to study SCI, female
rats are used. This study examined the efficacies of
MnTBAP and MPSS in improving neurological deficits
in four groups of female rats (200–225 g): sham control
(N=4), SCI treated with MnTBAP, MPSS or saline as ve-
hicle control (N=8 for the three injured groups). SCI-
induced neurological deficits were evaluated by the
Basso-Beattie-Bresnahan locomotor rating scale (BBB-
test) and the inclined plane test for 10 weeks. In the
sham-operated control group, animals underwent the
same surgical procedures but no impact injury was
performed. All experiments were triple blinded.
Animal preparation, drug administration and impact injury
The rats were given 0.1 mg/kg buprenorphine subcuta-
neously (s.c.) 15 min prior to anesthesia and then
anesthetized with pentobarbital (50 mg/kg, i.p.). After a
laminectomy, the exposed cords were injured on vertebra
T10 by a 10 g rod dropping 2.5 cm onto the exposed cord
(25 g.cm force) using the NYU device. Then, the muscle
and skin were sutured and 10 ml saline was injected (ip)
to prevent dehydration. The body temperature of the rat
was maintained using a heating pad during surgery and
until waking up. To avoid an additional incision on L5 for
intrathecal drug delivery which would affect the accuracy
of behavioral tests, drugs were administered by iv or ip
injection for behavioral tests. We previously demonstrated
that MnTBAP (10 mg/kg) given by ip injection signifi-
cantly reduces neuron loss [53]. In the present study, 10
mg/kg of MnTBAP or saline was given ip for behavioral
tests. The standard regimen of MPSS established for
clinical treatment of SCI was given by iv injection. The
first dose of MnTBAP (10 mg/kg) or MPSS (30 mg/kg)
was given at 4 h post-SCI followed by one half of the first
dose 2 h later. These rats were housed in a temperature
and humidity controlled room with a 12 h light/dark
cycle. In the first week following SCI, the bladder was
emptied manually until the voiding reflex was recovered;
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minimize the impairment or discomfort of injured rats.
The body weight of the animal was monitored for 10
weeks during behavioral tests. Since only the hindlimbs
were paralyzed, the rat could still reach food and water.
BBB-test
The motor function of rats was assessed using the BBB
locomotor rating scale as reported [54,55]. The test is
designed to assess progressive locomotor recovery after
SCI. The open field is simply a circular pool of 1 meter in
diameter. In order to observe animal locomotion, pretest
training of animals was required. Before injury, the rats
were exposed to the testing environment twice a day for 5
days. Each rat was handled several times during each 30–
60 min session so that they no longer showed signs of fear,
and became accustomed to being picked up and walked
continuously in the open field environment. Then the rats
were individually placed in the open field for 4 min to as-
sure that all subjects consistently obtained a maximum
score of 21. After SCI, the animals were evaluated for hind
limb motor function, either alone for 4 min or in pairs for 5
min, at day 3, and weekly from 1 – 10 weeks by two
blinded observers. Briefly, this scale involves closely moni-
toring limb movement, weight-bearing capability, coordin-
ation, and gait with scores ranging from 0 (complete
paralysis) to 21 (normal locomotion) corresponding to fully
coordinated and proper gait, movement at all joints, weight
support capability, and appropriate limb, body, and tail po-
sitioning. Two examiners were positioned across from each
other to observe both sides of the rat.
Inclined plane test
The rat was placed on an inclined plane covered by a
rubber mat (with 0.6 mm deep grooves) constructed as
reported [56,57]. The plane can be adjusted to different
slopes to measure the animal's ability to maintain its body
position for 5 sec without falling. The animal was placed on
the board three times at each of two positions: right side up
and left side up. The average score for the two positions
was used. The angle of the board was increased from 0°
until the rat could only maintain its position for 5 seconds.
Final readings to the nearest 5° were taken for the station-
ary positions. All animals were assessed at day 3, and every
week from 1 to 10 weeks after SCI.
Statistical analysis
Data were expressed as mean ± SEM. Two-way repeated
measures analysis of variance (RMANOVA) was used to
compare the time courses of ROS elevation between
MnTBAP- and saline-treated, MPSS- and saline-treated,
and between MnTBAP- and MPSS-treated groups.
Two-way RMANOVA followed by all pairwise multiple
comparison (Bonferroni t-test) was also used to comparethe differences between MnTBAP and saline treatment in
protection against MLP and protein nitration, and the dif-
ferences between MnTBAP and saline, MPSS and saline,
MnTBAP and MPSS in reducing neurological dysfunction.
One-way analysis of variance (ANOVA) followed by the
Tukey test was used to compare the differences in the levels
of ROS among different treatment groups in in vitro experi-
ments. The paired t-test was used to assess differences
between average post-injury and average pre-injury H2O2
and O2
•- levels in their time courses of production. P < 0.05
was considered a statistically significant difference.
Results
MnTBAP versus MP on reducing elevated ROS following
SCI
MnTBAP and MP both reduced SCI-elevated H2O2
concentrations
The time course of H2O2 elevation following SCI was
measured in vivo by microdialysis sampling and HPLC
analysis. The abilities of MnTBAP and MP to reduce
SCI-elevated H2O2 were evaluated by administering the
optimal dose of MnTBAP (4 mg/kg) and the equivalent
standard regimen of MPSS ((bolus dose plus mainten-
ance dose for a total of 9.24 mg/kg as described in the
Methods) into the intrathecal space of the rat spinal
cord. Figure 1 illustrates the time courses of H2O2
concentration changes in the extracellular space follo-
wing SCI in saline-treated, MnTBAP-treated, and
MPSS-treated groups. Owing to the variation of H2O2
concentrations among animals, the H2O2 concentrations
measured in the microdialysates were normalized: the
average basal level of H2O2 from the three pre-injury
time points for each animal was considered to be 100,
and the post-injury concentration measured at each time
point was presented as the percentage of the basal level.
The H2O2 levels in each rat during the basal period
(time points 1–3) and during the post-SCI period (time
points 4–18) were averaged and a paired t-test was
performed to compare the differences in H2O2 levels be-
tween post-injury and pre-injury in their time courses of
production. In the saline-treated group, the levels of
H2O2 increased in the first post-injury sample (20 min)
and remained elevated for 5 h. The average H2O2 level
during the post-trauma period (116 ± 2.5%, mean ± SEM)
was statistically significantly higher (p=0.005) than the
average pre-injury H2O2 level (100.0 ± 5.1%). In the
MnTBAP-treated group, the average level of H2O2 in the
post-trauma period was 100.3 ± 2.5% (mean ± SEM) of the
average pre-injury level (100.0 ± 6.7%, mean ± SEM), not
significantly different (p=0.9). In the MPSS-treated group,
the average level of H2O2 in the post-trauma period was
100.4% ± 2.7% (mean ± SEM) of the average pre-SCI level
of H2O2 (100.0 ± 6.3%, mean ± SEM), also not significantly




























Figure 1 The time courses of extracellular H2O2 concentration changes following impact injury to the rat spinal cord in saline-treated,
MPSS-treated, and MnTBAP-treated groups. The procedure was described in detail in the Methods section. After three microdialysates were
collected at 20-min intervals to establish a basal level, a weight was dropped at time 0 onto the cord (25 g·cm), and sampling was continued for
another 5 h at 20-min intervals. A single dose of MnTBAP (4 mg/kg) or the equivalent intrathecal standard regimen of MPSS (bolus dose plus
maintenance dose for a total of 9.24 mg/kg as described in the Methods) was administered into the intrathecal space of the cord through a
catheter implanted in the terminal cistern. The samples were collected in vials containing a solution of FeCl2 and salicylate. H2O2 in the
microdialysates were converted to ● OH in the collecting vials by the Fenton reaction. The ● OH produced in the collecting vials rapidly attacks
salicylate to produce 2,3- and 2,5-DHBA. The salicylate hydroxylation products 2,3- and 2,5-DHBA were analyzed by HPLC with electrochemical
detection. The 2,3-DHBA was calibrated to the amount of H2O2. Clearly, both MnTBAP and MP reduced H2O2 to its basal level.
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MPSS both significantly reduced the post-SCI H2O2 con-
centration to its pre-SCI levels – a 100% reduction.
Two-way RMANOVA was used to compare the differ-
ences of post-injury levels of H2O2 between different
treatment groups. The post-injury H2O2 levels in both
MnTBAP-treated and MPSS-treated groups were signifi-
cantly lower than those for the saline-treated group
(p<0.001 for both agents). There were no significant dif-
ferences in post-injury levels of H2O2 between MPSS-
treated and MnTBAP-treated groups (p=1.0). MnTBAP
(4 mg/kg) and MPSS (9.24 mg/kg) administered intra-
thecally both significantly reduced the level of H2O2 in
the extracellular space to the basal level, indicating a
similar ability to attenuate elevated H2O2 following SCI.
MnTBAP, but not MP reduced SCI-elevated O2
•-
concentrations
The time course of O2
•- elevation following SCI was mea-
sured in vivo by microcannula sampling the O2
•- -
reduced cytochrome c and measuring the absorbance of
reduced cytochrome c spectrophotometrically. The abil-
ities of MnTBAP and MP to reduce SCI-elevated O2
•-
were similarly evaluated, as for H2O2. Figure 2 illustrates
the time course of O2
•- level changes in the extracellular
space of the cord following SCI in the same three groups
of rats, as for H2O2. The levels of O2
•- were similarly nor-
malized and statistically analyzed, as for H2O2. In thesaline-treated group, the levels of O2
•- increased in the first
post-injury sample and remained elevated for 5 h. The
average level of O2
•- in the post-trauma period (157 ± 4.1%,
mean ± SEM) was significantly higher (p<0.001) than the
average pre-injury O2
•- levels (100.0 ± 2.9%, mean ± SEM).
In the MnTBAP-treated and MPSS-treated groups,
the average post-SCI levels of O2
•─ were 132 ± 4.7%
(mean ± SEM) and 165 ± 4.3% (mean ± SEM) respectively,
which were significantly higher than the average pre-injury
levels of O2
•- (100.0 ± 1.4% and 100.0 ± 2.6%, p<0.001).
Comparison of the time course of post-injury levels of
O2
•- in the extracellular space of the cord between saline-
treated and drug-treated by RMANOVA demonstrated
that the optimal dose of MnTBAP significantly reduced
post-injury O2
•- levels (p<0.001). However, there was no
significant difference in the post-injury O2
•- levels be-
tween saline-treated and MPSS-treated groups (p=0.3).
The post-injury O2
•- levels in the MnTBAP-treated group
were also significantly lower than those for the MPSS-
treated group (p<0.001). The optimal dose of MnTBAP
significantly reduced the elevation of O2
•- by approxi-
mately 50% compared with the vehicle- treated group,
whereas the standard regimen of MP did not attenuate
the elevation of O2
•─.
MnTBAP versus MP on scavenging ROS in vitro
In vitro testing was completed to explore the mechanism





















Figure 2 The time courses of extracellular O2
• ─ concentration changes following impact injury to the rat spinal cord in saline-treated,
MPSS-treated, and MnTBAP-treated groups. The procedure was described in detail in the Methods. O2
• ─ was captured by perfusing
cytochrome c through the microcannula. After three samples were collected at 20-min intervals to establish the basal level, a weight was
dropped at time 0 onto the cord (25 g·cm) and sampling was continued for another 5 h at 20-min intervals. MnTBAP and MPSS were
administered similarly, as in Figure 1. The perfusates were collected, centrifuged, and the absorbance of reduced cytochrome c was measured
spectrophotometrically. MnTBAP, but not MP, significantly reduced O2
• ─ levels.
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O2
•- measured in in vitro experiments. The concentrations
of H2O2 and O2
•- in the MnTBAP- or MPSS-treated groups
were normalized as the percentage of the ACSF-treated
group. One-way ANOVA followed by the Tukey test was
used to compare the differences in the levels of H2O2 and
O2
•- among different treatment groups. (A) The concentra-
tion of H2O2 in the MnTBAP-treated group (38.7 ± 3.4%,
mean ± SEM) was significantly lower than that in the
ACSF-treated group (100.0 ± 4.8%, mean ± SEM,
p<0.001) and in the MPSS-treated group (99.1 ± 3.0%,
mean ± SEM, p<0.001). There was no significant diffe-
rence (p=0.9) in the concentrations of H2O2 between
MPSS-treated and ACSF-treated groups. The in vitro
experiment demonstrated that MnTBAP significantly
reduced H2O2 levels to less than 40% of the levels of
vehicle treatment, whereas MP did not reduce H2O2.
(B) The O2
•- levels in the MnTBAP-treated group
(76.8 ± 0.8%, mean ± SEM) were significantly lower
than those in the ACSF group (100.0 ± 2.3%, mean ± SEM,
p<0.001) and in the MPSS-treated group (100.8 ± 0.8%,
mean ± SEM, p<0.001). There was no difference in the O2
•-
levels between MPSS-treated and ACSF-treated groups
(p=0.9). This in vitro experiment demonstrated that
MnTBAP significantly reduced O2
•- levels to less than 80%
of the levels in the vehicle-treated group, but MPSS did
not reduce O2
•- levels. The O2
•- levels in the MnTBAP-
treated group were significantly lower than those in the
MPSS-treated group (p<0.001). It can be concluded that
MnTBAP directly scavenges both H2O2 and O2
•-; however,
MPSS had no effect on levels of either H2O2 or O2
•-
compared with their levels in the ACSF-treated group.MnTBAP protects against oxidative stress after SCI
We have previously compared the antioxidative abilities of
MnTBAP with the standard regimen of MP, and demon-
strated that MnTBAP at a dose of 2.5 mg/kg significantly
reduced MLP, protein nitration and neuron loss, but MP
had no effect on either [45]. The present study evaluated
the optimal dose of MnTBAP protection against oxidative
stress in neurons. The spatial profiles of oxidative stress in
neurons were established by counting the HNE- and Ntyr-
positive neurons in the spinal cord sections immuno-
histochemically stained with anti-HNE and anti-Ntyr
antibodies at different distances from the epicenter.
Protection by MnTBAP was evaluated by comparing
the counts in the sections treated with the optimal
dose of MnTBAP and with saline as vehicle controls
using two-way RMANOVA followed by all pairwise
multiple comparison (Bonferroni t-test).
Figure 4 (upper panel) provided photomicrographs of
anti-HNE immuno-stained sections 1.55 mm rostral to
the epicenter in MnTBAP- and saline-treated groups.
The MnTBAP-treated section (C) had fewer HNE-
positive neurons compared with the saline-treated group
(B). D-F presented images of a section double-immuno
-fluorescence-stained with anti-HNE and anti-NSE anti-
bodies in a MnTBAP-treated cord to verify the presence
of HNE-positive neurons. The neurons stained with NSE
(E) showed normal morphology. The same sections
stained with HNE (D) showed not only a reduced num-
ber of HNE-positive neurons compared with E, but also
partial HNE staining in some HNE-positive neurons be-
cause MnTBAP attenuated MLP in neurons. The




































ACSF MP      MnTBAP
Treatments
Figure 3 In vitro comparison of the abilities of MnTBAP and MP to remove H2O2 (A) and O2
• ─ (B). The experimental groups were described
in the Methods section and in Tables 1 and 2. The levels of H2O2 and O2
• ─ were measured by HPLC or spectrophotometrically, as described in
Figures 1 and 2. MnTBAP, but not MPSS, significantly reduced both H2O2 and O2
• ─ levels.
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entire neurons. MnTBAP protection against MLP was
quantified by counting numbers of HNE-positive neurons
in the sections 0.55 to 2.55 mm rostral to the epicenter in
MnTBAP- and saline-treated groups. Comparison of the
counts between the two treatment groups demonstrated
that 4 mg/kg of MnTBAP significantly (P<0.001) decreased
the number of HNE-positive neurons in the ventral gray
matter of the cord. The number of HNE-positive neurons
in the MnTBAP-treated group was significantly decreased
(P<0.001 for all) at 1.55 (2.1 ± 0.7), 2.05 (7.5 ± 0.32) and
2.55 (9.6 ± 0.6) mm compared with vehicle-treated sections
at 1.55 (7.6 ± 1.2), 2.05 (11.4 ± 0.59), and 2.55 (13.8 ± 0.41)
mm rostral to the epicenter (Figure 4 lower panel).
Figure 5 (upper panel) presents anti-Ntyr-immuno-
stained sections 2.6 mm rostral to the epicenter insaline-treated (A) and MnTBAP-treated (B) groups. The
MnTBAP-treated section had fewer Ntyr-positive
neurons and more normal morphology of neurons
compared with the saline-treated section. The identities
of the Ntyr-positive neurons were further verified by
double-immuno-fluorescence staining with anti-Ntyr (D )
and anti-NSE (C) antibodies from a saline-treated
section 2.6 mm from the epicenter, and the double-
stained nitrated proteins in neurons were co-localized
(E). MnTBAP protection against protein nitration was
quantified by counting the Ntyr-positive neurons in the
sections 0.6 to 3.1 mm rostral to the epicenter at 0.5 mm
intervals in MnTBAP- and saline-treated groups, and
counts were compared. The overall comparison between
the two treatment groups demonstrated that treatment by
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Figure 4 MnTBAP protects against MLP. The animal experiment, spinal cord injury, and tissue processing were described in the Methods
section. After the epicenter was located, the sections 0.55 to 2.55 mm rostral to the epicenter were immuno-stained at 0.5-mm intervals with an
anti-HNE antibody. Upper panel, photomicrographs of anti-HNE antibody immuno-stained sections. A, lower magnification of a HNE stained
spinal cord section showing the morphology of cord section and indicating the cell counting area defined by horizontal and vertical lines drawn
crossing the central canal in the center of the sections, as described in cell counting in the Methods section. B and C, higher magnification of
HNE stained spinal cord sections at 1.55 mm rostral to the epicenter. B, saline-treated and C, MnTBAP-treated sections. The colored panels (D-F)
show double-immuno-fluorescence staining with anti-HNE (D, green) and anti-NSE (E, red) antibodies, and immuno-colocalization of D and E
(F, yellow). The color photomicrographs are at a higher magnification. Scale bars are 100 μm. Lower panel, spatial profile of MnTBAP protection
against MLP. The HNE-positive neurons were counted, and the counts compared between MnTBAP-treated and the vehicle-treated animals at
different distances from the epicenter. MnTBAP significantly (indicated by an asterisk*) reduced the number of HNE-positive neurons in the
sections 1.55 to 2.55 mm from the epicenter. Error bars, mean ± S.E.M.































Figure 5 MnTBAP protects against protein nitration. The sections 0.6 to 3.1 mm rostral to the epicenter in the animals, as shown in Figure 4,
were immuno-stained at 0.5-mm intervals with an anti-Ntyr antibody. Upper panel, photomicrographs of rat spinal cord sections 2.6 mm rostral
to the epicenter immuno-stained with an anti-Ntyr antibody. A-B, lower magnification; A’-B’, higher magnification of A-B. A-A’, saline-treated and
B-B’, MnTBAP-treated sections. Fewer Ntyr-positive neurons appeared in the MnTBAP-treated sections. C-E, immuno-colocalization of a double-
immuno-fluorescence-stained section with an anti-Ntyr antibody (D, green) and an anti-NSE (C, red) antibody, and immuno-colocalization of C
and D (E, yellow). Scale bars100 μm. The lower panel presents the quantitative results of MnTBAP protection against protein nitration obtained by
counting Ntyr-positive neurons in the sections at different distances from the epicenter. Comparison of the counts between the sections treated
by optimal dose of MnTBAP and those treated by vehicle indicates that MnTBAP significantly (indicated by an asterisk*) reduced the number of
Ntyr-positive neurons in the sections 1.1 to 3.1 mm to the epicenter. Error bars, mean ± S.E.M.
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cord (P<0.001). The number of Ntyr-positive neurons
in the MnTBAP-treated group was significantly de-
creased at 1.1 (1.6 ± 0.55, P=0.03), 1.6 (2.9 ± 0.11,
P<0.001), 2.1 (7.7 ± 0.13, P<0.001), 2.6 (9.4 ± 0.29,
P<0.001) and 3.1 (13.3 ± 0.31, P<0.001) mm compared with
vehicle-treated sections at 1.1 (2.3 ± 0.65), 1.6 (5.2 ± 0.25),
2.1 (12.0 ± 0.32), 2.6 (13.0 ± 0.27), and 3.1 (15.9 ± 0.30)
mm rostral to the epicenter (Figure 5, lower panel).
The number of immuno-positive neurons increased
with distance from the epicenter; this is not due to more
neurons being oxidized or nitrated at the longer distance
than at the shorter distance from the epicenter. Rather it
is simply because most neurons were lost near theepicenter, and more neurons survived farther from the
injury center, providing a larger number of neurons to
be oxidized and labeled as HNE-positive or Ntyr-positive
neurons.
MnTBAP versus MP on protection against neurological
dysfunction after SCI
SCI-induced neurological deficits were evaluated by the
BBB test (Figure 6A) and the inclined plane test (Figure 6B)
for 10 weeks. Behavioral test scores were compared by the
two-way RMANOVA followed by all pairwise multiple
comparisons between treatments: MnTBAP versus
saline, MP versus saline, MnTBAP versus MP, and
between treated and sham control. Post-SCI treatment






































Figure 6 MnTBAP versus MP on locomotor recovery following SCI as assessed by the BBB-test and inclined plane test. The spinal cords
of rats were injured at vertebra T10 (25 g.cm) using the NYU device. The behavioral tests were performed on animals treated with MnTBAP (ip),
MPSS (iv), saline (ip), and a sham control group as described in the Methods section. The first dose of MnTBAP (10 mg/kg) or MPSS (30 mg/kg)
were given at 4 h post-SCI and followed by one half of the first dose 2 h later. All experiments were triple blinded. A. results of BBB-test. B. results
of inclined plane test. Error bars: mean ± SEM. Clearly, MnTBAP more effectively attenuates the neurological deficits on both tests than does MP.
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BBB scores (p < 0.001) compared to saline-treated
with no difference at 3 days (p=0.9) and significant
differences at all other time points (p=0.03 for 1 week and
p<0.001 for 2–10 weeks). MnTBAP also significantly
increased the inclined plane angles (p<0.001) with no dif-
ference at 3 days and 1 week (p=1 and 0.8 respectively);significant differences started at 2 weeks (p=0.006 - 0.01
for 2–4 weeks and p<0.001 for 5–10 weeks). These results
demonstrate that antioxidant therapy with MnTBAP
significantly improved neurological dysfunction compared
to the vehicle treatment and disproves the belief that anti-
oxidant therapy is only effective shortly after SCI and of no
value for longer term recovery. The standard regimen
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logical recovery (p<0.001 for both tests) compared to
saline-treated. However there are no significant differ-
ences at any time point for both tests (p=0.2-1.0 for
BBB and 0.5-1.0 for inclined plane tests). The scores
in MnTBAP-treated animals are significantly better than
MPSS-treated (p<0.001 for both tests). The significant
differences started at 6 weeks (p=0.02 - 0.01) for the BBB
test, with no difference at 3 days to 5 weeks (p=0.2-1.0).
There were no difference at any time (p=0.2-1.0) for the in-
clined plane test. This demonstrates that 4 h post-SCI
treatment with MnTBAP is more effective than 4 h post-
SCI treatment with MPSS for improving neurological
recovery after SCI. The scores for all treatment in injured
animals were significantly worse compared to sham control
(p<0.001 for all), indicating that pharmaceutical treatments
alone cannot improve the dysfunction to a normal level.
Discussion
In order to evaluate the potential of the catalytic antioxi-
dant MnTBAP for the treatment of SCI, the present
study characterized its abilities to scavenge ROS, to pro-
tect against oxidative stress in neurons and to ameliorate
neurological dysfunction following SCI. The abilities to
remove ROS and to improve functional recovery were
compared between MnTBAP and MP, in addition to our
previous comparison of the antioxidative and neuron
protective effects between them [45] given that MP is
the only drug used clinically for treating SCI.
By microdialysis or microcannula sampling and analysis
of microdialysates or perfusates by HPLC or spectrophoto-
metrically, we demonstrated that both H2O2 and O2
•- levels
in the extracellular space of the rat spinal cord significantly
increased following SCI (25 g.cm). The approximately 16%
increase in average post-SCI H2O2 and the approximately
60% elevation of the average post-SCI O2
•─ level compared
with the pre-injury level are less than the 30% and 100%
increases of H2O2 and O2
•- levels induced by a more severe
injury (75 g.cm), as we reported previously [16,17]. There-
fore, the production of H2O2 and that of O2
•- are positively
significantly correlated with the severity of impact injury.
The abilities of MnTBAP and MP to reduce ROS were
compared in vivo and in vitro. We demonstrated for the
first time in vivo that the optimal dose of MnTBAP
administered directly into the intrathecal space of the
cord significantly reduced the elevation of H2O2 in the
extracellular space to the basal level (Figure 1) and sig-
nificantly reduced the elevation of O2
•- by approximately
50% following SCI, compared with the levels in the
vehicle-treated animals (Figure 2). In contrast, the stand-
ard regimen of MPSS failed to significantly reduce the
elevation of O2
•─ (Figure 2). In vitro experiments were
carried out to explore the possibly different mechanisms
by which MnTBAP and MP attenuate concentrations ofH2O2 and O2
•- (Figure 3). We demonstrated that treat-
ment by MnTBAP significantly reduced H2O2 levels to
approximately 40% of the levels in ACSF-treated sam-
ples, and significantly reduced O2
•- levels to approxi-
mately 80% of the levels in ACSF group. In contrast, MP
had no effect on levels of either H2O2 or O2
•- compared
with those of corresponding ACSF-treated groups. Our
in vitro experiment demonstrated that MnTBAP can
scavenge H2O2 and O2
•-, whereas MP could not scav-
enge these ROS. Therefore the ROS-scavenging ability
of MnTBAP should contribute to the reduction of
SCI-elevated H2O2 and O2
•-.
The catalase activity of most metalloporphyrins is less
than 1% of that of native catalase [35]. The SOD activity
of MnTBAP is 41 units/mg (the unit is defined as the
amount of compound that inhibits the reduction of cyto-
chrome c by 50%), and the catalase activity of MnTBAP
is only 0.81/min (pseudo first-order rate constant for
H2O2 decay) [58]. Our results demonstrated that with its
“poor” catalase activity and greater SOD activity, MnTBAP
was able to completely remove the overproduced H2O2 but
only removed 50% of the overproduced O2
•- in vivo in our
SCI model. Given the optimal dose of MnTBAP (4 mg/kg),
approximately 1 mg of MnTBAP was administered to a
250 g rat. Therefore, MnTBAP equivalent to 41 units of
SOD activity was administered to a rat. According to this
definition, if one unit inhibits the reduction of cytochrome
c by 50%, then, 41 units should be much more than enough
to inhibit all reduction of cytochrome c by O2
•-. However, in
our study 41 units inhibited the reduction of cytochrome c
by only 50%, a forty fold lower SOD activity in our in vivo
experiment than expected [58]. In contrast, the lower
catalase activity of MnTBAP, as reported [58],
brought the SCI-induced H2O2 elevation down to the
basal level. Our in vitro experiment, consistent with
our in vivo finding, also showed that MnTBAP proved
more effective at scavenging H2O2 than it did O2
•- . Al-
though the mechanism of the dramatic difference between
the report [58] and both our in vivo and in vitro findings
was not explored in this study, our results support the
statement that “MnTBAP is not an SOD mimic, as it has
negligible SOD-like activity” by Batinić-Haberle et al. [36].
The effectiveness of MnTBAP protection against oxida-
tive stress was examined spatially around the injury epi-
center. Because the neurons in the cord near the epicenter
were killed immediately by acute mechanical injury, they
could not be rescued by pharmaceutical intervention.
Conversely, the cells far from the epicenter largely
remained intact, so treatment should also not have much
effect in this area, as reported [53]. Because substantial
effects of the drug treatment can only be seen in a limited
area, a spatial profile more accurately indicates the area of
protection at the cellular level. Our spatial profiles indi-
cated that 4 mg/kg of MnTBAP significantly reduced the
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2.55 mm rostral to the epicenter (Figure 4) and Ntyr-
positive neurons in the sections 1.1 to 3.1 mm rostral to
the epicenter (Figure 5) compared with numbers in the
vehicle-treated group. MnTBAP at 4 mg/kg reduced MLP
and protein nitration in a larger area than in our previous
study [45] in which 1 mg/kg MnTBAP was also given
intrathecally: 1 mm in length at 4 mg/kg and 0.5 mm long
at 1 mg/kg for MLP, and 2.0 mm in length at 4 mg/kg and
0.5 mm at 1 mg/kg for protein nitration. The area of
significant protection also started approximately 1 mm
closer to the epicenter for 4 mg/kg than for 1 mg/kg. This
comparison indicated that protective effects of MnTBAP
are correlated with doses administered. The results in the
present study together with our previous publications
[44,45,53] indicated that MnTBAP ameliorates secondary
damage within the boundary area. SCI treatment should
be greatly improved by combining antioxidant therapy to
save cells in the boundary area with other manipulations
such as transplantation of stem cells, Schwann cells, and
nanoparticles, etc. to restore the neurons and to repair
and regeneration of axons in the injury epicenter. [59-61].
RS can cause injury by directly oxidizing the major
cellular components. Sulfhydryl group in proteins is
very susceptible to oxidation, nitration, nitrosation,
and nitrosylation. Since the oxidative defense enzymes,
such as SODs, catalase, GPx, thioredoxin, etc., are all
sulfhydryl-containing enzymes, they may suffer function-
distorting oxidative modification. MnTBAP scavenges
SCI-induced RS, thereby protecting against oxidation
and nitration of these antioxidant enzymes – helping res-
toration of their enzymatic activity. Functional recovery of
defense enzymes, in turn, further reduces RS production.
This positive feedback mechanism enhances the effects of
MnTBAP protection. RS can cause injury by acting as
intracellular death signals that lead to changes in expres-
sion of proteins, and by acting as modulators of the redox
state. RS also have physiological functions. In redox cycles,
the primary signal transducers are not large proteins but
small redox-active molecules. ROS (e.g. O2
•─, H2O2), and
RNS (e.g. nitric oxide, S-nitrosothiols and ONOO-) can
mediate redox signaling [62]. Therefore, in addition to
catalytically scavenging a wide range of RS, other mecha-
nisms such as modulating RS-based redox signaling
pathways, and regulating cellular transcription activ-
ity may also contribute to the beneficial effects of
metalloporphyrins [36]. It was reported that MnTBAP
attenuated the nuclear translocation of apoptosis-
inducing factor and the subsequent DNA fragmenta-
tion induced by ROS after permanent focal cerebral
ischemia in mice [63]. So, in addition to their enzym-
atic catalyzing scavenging activities, more complicated
mechanisms may be involved in our in vivo finding
that MnTBAP reduced elevation of deleterious ROS,attenuated oxidative stress in neurons, and improved
functional recovery after SCI.
The mechanisms by which the steroid MP protect against
MLP and neurological deficits lies in its anti-oxidative and
anti-inflammatory activities. In contrast to the effects of
MnTBAP, our in vitro results demonstrated that MP had
no effect on the levels of H2O2 and O2
•-. This is consistent
with the published report that MP does not directly trap
radicals [64]. The activity of the oxidative defense enzyme
GPx in erythrocytes of the rat was inhibited after SCI and
MP restored GPx activity to near-basal levels [65]. Similar
tendencies were also found for the activities of catalase and
GPx in the spinal cord tissues of rats following SCI and MP
treatment [66]. This suggests that the in vivo reduction of
H2O2 by MP following SCI probably occurs indirectly
through pathways, such as anti-inflammatory activities
[67] and restoration of the activities of oxidative
defense enzymes [65,66]. Our previous study demon-
strated that MP significantly reduced the extracellular
release of prostaglandin F2α (PGF2α), a membrane hydroly-
sis product, following SCI. It blocked PGF2α-induced
•OH
and MDA production. However, unlike MnTBAP, MP did
not significantly reduce Fenton’s reagent-induced MDA
production in the rat spinal cord, even though the MDA
concentration was below the concentration induced by
PGF2α. This suggests that 1) MP cannot directly scavenge
•OH, 2) its “antioxidant” effect is probably a consequence
of interrupting the production of toxic hydrolysis products,
and 3) the MLP is triggered by hydrolysis product-induced
free radicals [68]. Therefore, the broad-spectrum RS
scavenger MnTBAP better attenuates oxidative damage
than does MP.
We previously measured the time course of protein
nitration by counting the Ntyr-positive cells in sections
stained by the anti-Ntyr antibody at different times post-
SCI [20]. We found that protein nitration peaked at 12 to
24 h post-SCI. In a recently published study, Carrico et al.
reported that Ntyr-positive and HNE-positive staining
increased starting from 3 h to as long as 1 and 2 weeks
post-SCI [26]. Christie et al. reported that after acute SCI
the levels of MDA rose quickly at 4 h, returned to baseline
at 12 h, and increased again by 24 h post-SCI, and the ele-
vation was sustained for 120 h post-SCI [28]. Luo et al.
reported that HNE-protein adducts increased in the
damaged cord as early as 4 h after SCI, reached a
peak level at 24 h, and remained significantly elevated
up to 7 days after SCI [69]. Therefore, in the present
study, the spatial profiles of MnTBAP protection against
oxidative stress were measured at 24 h post-SCI. This time
point was within the peak region of protein nitration, and
production of MDA and HNE-protein adducts.
Although the regimen of MPSS applied in our study
was the standard one for the clinical treatment of SCI, it
was originally developed by using experimental animals.
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compared with 15 and 60 mg/kg [70]. The bolus dose of
30 mg/kg plus follow-up administration was also used in
experimental SCI of rats [71-73]. In a dose–response
study using a ventral compression injury model, the best
results were yielded when MPSS was administered in the
rats with a bolus dose of 30 mg/kg at 30 min post-SCI
followed by a second injection of 15 mg/kg (a total of 45
mg/kg) or with a 60 mg/kg bolus at 30 min post-SCI [74].
This demonstrates that the standard regimen of MPSS for
the clinical treatment of SCI is also suitable for rats.
Therefore, the standard clinical regimen of MPSS was
applied in the present study.
Administering MP within 8 hours improves neuro-
logical recovery in SCI. However, the high dose of MP is
ineffective and possibly even deleterious when given
more than 8 hours post-SCI [43,75,76]. This indicates
that 8 h is an effective time window for MP treatment.
In many studies of experimental SCI treated with MP,
MPSS was given immediately following SCI (0 h post-SCI).
Unfortunately, in clinical practice patients can rarely be
treated at 0 h post-injury. We demonstrated that the time
window for MnTBAP to reduce oxidative damage and
neuron death was at least 12 h after SCI [44]. Therefore, in
addition to comparing the efficacy of 4 h post-SCI treat-
ment with MnTBAP and MP to protect against oxidative
stress and cell death as we reported [45], the present study
further compared the effectiveness of 4 h post-SCI treat-
ment with MnTBAP and MP in functional recovery after
SCI. This is not only within the effective time window for
both MP and MnTBAP, but also a more practical time
window for clinical usage. We demonstrated that post-SCI
treatment with 10 mg/kg MnTBAP (ip), or with the stand-
ard MP regimen (iv), both significantly increased BBB and
inclined plane scores compared to vehicle treatment. How-
ever, the scores in MnTBAP-treated animals were signifi-
cantly better than in MP-treated animals, demonstrating
that post-SCI treatment with MnTBAP is more effective
than MP for improving neurological dysfunction after SCI.
MnTBAP was reported as poorly penetrating the
blood brain barrier [49], so it is not a favorable candidate
for antioxidant therapy for central nervous system injury.
We also demonstrated that the MP’s blood–spinal cord
barrier penetrating ratio was much higher than MnTBAP
(20% versus 4%) [50]. However, our results of behavioral
tests demonstrated that with lower ability of penetrating
the blood–spinal cord barrier, MnTBAP reached appropri-
ate targets and more effectively improved the functional
recovery than the standard treatment of SCI by MP, further
supporting the candidacy of MnTBAP in treating SCI.
Conclusion
1) By microdialysis or microcannula sampling and bio-
chemical analysis, the present study demonstrated for thefirst time in vivo in a rat SCI model that the intrathecal
optimal dose of MnTBAP significantly reduced the eleva-
tion of both H2O2 and O2
•- in the extracellular space of the
rat spinal cord following SCI. In contrast, the standard regi-
men of MPSS failed to significantly reduce the elevation of
O2
•─ compared with levels in vehicle-treated animals. Our
in vitro results demonstrated that MnTBAP can scavenge
both H2O2 and O2
•-, but showed that MPSS has no ability
to remove either. 2) By measuring the spatial profile of
MnTBAP protection against MLP and protein nitration in
neurons, this study established the effective areas for the
optimal dose of MnTBAP protection to reduce oxidative
damage after SCI. 3) By behavioral tests, this study demon-
strated for the first time that 4 h post-SCI treatment with
MnTBAP (10 mg/kg, ip) was significantly more effective in
reducing neurological dysfunction than the standard regi-
men of MP (iv). This is a most important criterion in deter-
mining the therapeutic potential of a candidate agent for
SCI treatment. These results provide evidence that the gen-
eration of ROS during the secondary damage cascade after
SCI is a cardinal factor leading to oxidative damage to neu-
rons, thereby causing neurological dysfunction. ROS cata-
lytic scavenging ability of MnTBAP is likely a major
factor in its protection against oxidative damage and
neurological dysfunction, possibly by a positive feedback
mechanism: MnTBAP removes ROS, thereby reducing
ROS-induced oxidative modification to the major cellular
components, including the antioxidative defense enzymes.
Activity restoration of these defense enzymes by MnTBAP,
in turn, further reduces ROS production. This positive
feedback mechanism would enhance the effects of
MnTBAP protection. Combination of the findings in the
present study and our previous publications [44,45] ranks
the broad spectrum scavenger MnTBAP as superior to
MP in removing ROS, thereby preventing oxidative dam-
age to cellular components and so ameliorating neuro-
logical recovery. Our results suggest that MnTBAP is a
potential candidate for antioxidant therapy following SCI.Abbreviations
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